

Demonstrating the Economic Health Benefit of using the PromarkerD In Vitro Diagnostic Test in the Prediction of Diabetic Kidney Disease

Email: info@promarkerd.com
Websites: www.promarkerd.com, www.proteomics.com.au

Burchenal W¹, Datar M¹, Peters KE², Fernandez GC², Morrison JC², Lipscombe RJ²
¹Boston Healthcare Associates, Boston, MA, USA, ²Proteomics International, Perth, WA, Australia

Presented at the Virtual ADA 81st Scientific Sessions
13-A Health Care Delivery – Economics
Poster 813-P



Background

- Diabetic kidney disease (DKD) develops in 1 in 3 people with type 2 diabetes (T2D) and is the leading cause of end-stage renal disease (ESRD).¹
- Most people with CKD (~90%) are unaware they have the disease,¹ with early detection and treatment essential to prevent further kidney injury.²
- DKD costs the US Medicare system \$50 billion annually.³
- PromarkerD is an innovative biomarker-based blood test that can predict future renal function decline in the next 4 years in people with T2D who have no or mild existing DKD (eGFR >30 mL/min/1.73m²).
- PromarkerD predicts incident DKD (reduction in eGFR to <60 mL/min/1.73m²) or eGFR decline ≥30% in people with baseline eGFR <60 mL/min/1.73m².
- PromarkerD test scores are categorized as low-, moderate- or high-risk to optimize DKD management.

Aim

- To develop a budget impact model to estimate the net savings to US payers over a 10-year time horizon from covering the PromarkerD test versus current standard-of-care (SOC) without PromarkerD.

Methods

- The total number of people with T2D and no/mild DKD (KDIGO categories G1-3b)⁴ in the US (~31 million)⁵ were included in the budget impact model (Figure 1).
- The budget impact model evaluated potential savings to US payers from covering the PromarkerD test versus SOC through: slower DKD stage progression; delayed or avoided dialysis and transplants; and reduction in dialysis crashes.
- The model also evaluated the potential relative costs associated with PromarkerD, including: PromarkerD test costs every 12, 8 or 6 months for low-, moderate-, and high-risk patients, respectively;² costs of preventative medications in high-risk PromarkerD patients (Table 1); treatment costs for each DKD stage, including costs associated with dialysis and transplant (Table 1).

Figure 1. Prognosis of CKD by GFR and albuminuria category.




Table 1. Annual Costs per Patient at Each DKD Stage.⁶⁻¹¹

Cost per Patient at Each DKD Stage	Annual Treatment Cost (USD)	Preventative Medications (PromarkerD High-Risk Patients) (USD)
Stage G1	\$16,257	\$1,031
Stage G2	\$18,288	\$1,421
Stage G3a	\$21,068	\$1,450
Stage G3b	\$30,800	\$2,082
Stage G4 (Non-Target)	\$40,537	N/A
Stage G5 (Non-Target)	\$70,219	N/A
ESRD		N/A
Treatment costs	\$109,783	
Dialysis	\$70,959	
Additional cost of dialysis crash	\$49,199 one time	
Transplant	\$262,000 one time	
Post-transplant care	\$40,000	

Methods

- Model assumptions and parameters were derived from prior literature and PromarkerD clinical studies.
- The prevalence of DKD by KDIGO categories was based on US population data.¹²
- Rates of DKD stage progression were estimated from prior PromarkerD clinical studies.^{13,14}
- Only high-risk patients were prescribed preventative medications, with 80% adherence assumed.¹⁵
- A 20% decline in DKD stage progression due to PromarkerD implementation compared to SOC was used. A range of progression rates were also assessed (5-35%).
- A provisional test price for PromarkerD was set at \$150 USD. Test prices of \$100 and \$200 were also used.
- Preventative medication costs were derived from the difference in medication costs between SOC and recommended medications for high-risk PromarkerD patients.
- Proportion of patients insured by Medicare vs. Commercial insurance was 60% vs. 40%, respectively.
- All savings and costs were inflation-adjusted to 2021 USD. A discount rate of 3% was used.¹⁷

Results


- Of the 31 million patients tested with T2D and no/mild DKD, 6.8 million were predicted by PromarkerD to be 'high-risk' and received additional preventative medications.
- PromarkerD testing could produce savings for US payers of \$473 billion over 10 years, against costs of \$89 billion, resulting in **net savings of \$384 billion over 10 years** (Table 2).

Table 2. Comparative Savings and Costs of using PromarkerD over SOC.

Budget Impact Model (Over 10 years)	Costs (USD)
Savings	\$473 billion
Costs	\$89 billion
Net Savings	\$384 billion


- The **total annual savings provided by PromarkerD equal the costs after 2 years**. Savings increase exponentially in subsequent years, far outweighing the associated costs compared to the current SOC without PromarkerD (Figure 2).

Figure 2. Annual (undiscounted) Savings for PromarkerD.



- The **breakeven point occurs at year 3**, after which the total savings are greater than the costs (Figure 3).


Figure 3. Cumulative (undiscounted) Savings versus Costs of PromarkerD Implementation.



Results


- Over 10 years, **most savings are associated with slowing the progression of DKD** (\$262 billion, 55% of total savings), compared to the savings from delaying or preventing dialysis and transplants (\$183 billion, 39%), or reduction in dialysis crashes (\$28 billion, 6%) (Figure 4).

Figure 4. Gross Present Value of Savings over 10 years by Category.



- In sensitivity analysis, assuming a 5% decline in DKD progression rate still resulted in net savings over 10 years (\$40-\$71 billion with a \$100-\$200 PromarkerD test). Net savings were also achieved at the 20% progression rate using a PromarkerD test price of \$100 (\$400 billion) and \$200 (\$369 billion) (Figure 5).

Figure 5. Net Present Value of Savings (discounted) from PromarkerD Implementation over 10 years.



Conclusions

- This economic study demonstrates that improved management of people with T2D through the use of early, accurate and cost-effective prognosis with the PromarkerD test could result in savings of \$384 billion over 10 years to US payers in the treatment of DKD.
- Employing this alternative PromarkerD testing regime over the current SOC would enable proactive early intervention for T2D patients at high-risk of DKD, thereby decreasing the need for expensive interventions such as dialysis and transplants, or unnecessary adoption of new therapeutic treatments in those at low-risk.

References

1. US CDC. Chronic Kidney Disease in the United States, 2021. <https://www.cdc.gov/kidneydisease/pdf/Chronic-Kidney-Disease-in-the-US-2021-h.pdf>
2. Tuttle KR, et al. Diabetic kidney disease: a report from an ADA Consensus Conference. *Diabetes Care*. 2014;37(10):2864-2883.
3. NIDDK United States Renal Data System 2020 Annual Data Report. <https://adr.usrds.org/2020>
4. KDIGO Chronic Kidney Disease Guideline Development Work Group Members. KDIGO 2012 Clinical practice guideline for the evaluation and management of chronic kidney disease. *Kidney Int Suppl*. 2013;3:1-150.
5. US CDC. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2020. <https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf>
6. Honeycutt AA, et al. Medical costs of CKD in the Medicare population. *J Am Soc Nephrol*. 2013;24(9):1478-1483. doi:10.1681/asn.2012040392
7. Knight TG, et al. Clinical and Economic Outcomes in Medicare Beneficiaries with Stage 3 or Stage 4 Chronic Kidney Disease and Anemia: The Role of Intravenous Iron Therapy. *AMCP*. 2010;16
8. Wang V, et al. The Economic Burden of Chronic Kidney Disease and End-Stage Renal Disease. *Seminars in Nephrology*. 2016;36(4).
9. Golestaneh L, et al. All-cause costs increase exponentially with increased chronic kidney disease stage. *American Journal of Managed Care*. 2017;23(10 Supplement):S163-S172.
10. Liu FX, et al. Economic Evaluation of Urgent-Start Hemodialysis Versus Urgent-Start Hemodialysis in the United States. *Medicine*. 2014;93(28).
11. Nephcare Kidney International. Transplant. <https://nephcare.org/livingwithkidneydisease/kidney-failure/transplant/>
12. Wang T, et al. Chronic kidney disease among US adults with type 2 diabetes and cardiovascular diseases: A national estimate of prevalence by KDIGO 2012 classification. *Diabetes and Metabolic Syndrome: Clinical Research and Reviews*. 2019;13(1):612-615.
13. Peters KE, et al. Identification of Novel Circulating Biomarkers Predicting Rapid Decline in Renal Function in Type 2 Diabetes: The Fremantle Diabetes Study Phase II. *Diabetes Care*. 2017;40(11):1548-1555.
14. Peters KE, et al. Validation of a protein biomarker test for predicting renal decline in type 2 diabetes: The Fremantle Diabetes Study Phase II. *J Diabetes Complications*. 2019; 33(12):107406.
15. Hugtenburg JG, et al. Patient Preference and Adherence Definitions, variants, and causes of nonadherence with medication: a challenge for tailored interventions. *Patient Preference and Adherence*. 2013;7-675.
16. Neuen BL, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. *Lancet Diabetes Endocrinol*. 2019;7(11):845-854.
17. Gold M, et al. *Cost-Effectiveness in Health and Medicine*. Oxford University Press; 1996.

Boston Healthcare Associates was paid to conduct this study as an independent consultant to Proteomics International.